« Return to News | Drug Sponsors

Amgen to create hundreds of jobs in Dublin

Tuesday, August 23, 2011 10:26 AM

US drug firm Amgen plans to create 100 high-tech jobs at a new factory in Dublin just months after it saved 280 jobs by taking over a Pfizer plant that was earmarked for closure, according to The Post.

Amgen plans to build a new manufacturing plant in Dun Laoghaire alongside the Pfizer plant it bought in May. Around 350 construction workers will be employed during the building of the 8,600 square meter factory and 3,000 square meter warehouse at the site on Pottery Road.

The new factory will be involved in manufacturing the next generation of drugs from Amgen, which makes treatments for cancer and other serious diseases.

Dun Laoghaire-Rathdown County Council previously granted permission to Pfizer for development on the site, but Amgen will submit a revised planning application.

The firm has informed local residents of its plans and invited them to visit the company on open days to find out more about the development. Amgen announced a deal in March to buy the existing Dun Laoghaire plant from Pfizer and took control of the facility in mid-May.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.